US eyes permanent change to digital health regulatory path

Developers of digital health tools have benefited from a truncated route to market during the COVID-19 crisis, and that could be made permanent if new FDA guidance is adopted.

Biogen bulks up pipeline with Sage drugs in $3bn deal

With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs f

Blue Oak taps AI specialist Exscientia for CNS drug discover...

US startup Blue Oak Pharma has joined a lengthening list of companies turning to Exscientia of the UK for its expertise in applying artificial intelligence to drug discovery.

Pear rolls out digital therapy for schizophrenia under FDA’s...

NICE rejects J&J’s Spravato for treatment-resistant depressi...

J&J seeks wider use of its Spravato antidepressant in US